BioCardia, Inc. Common Stock (BCDA) is a publicly traded Healthcare sector company. As of May 21, 2026, BCDA trades at $0.97 with a market cap of $10.24M and a P/E ratio of -0.76. BCDA moved -2.22% today. Year to date, BCDA is -27.56%; over the trailing twelve months it is -53.06%. Its 52-week range spans $0.84 to $3.20. Analyst consensus is buy with an average price target of $15.50. Rallies surfaces BCDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioCardia Earns FDA Breakthrough Designation, Secures $20K Medicare Reimbursement: BioCardia Inc received FDA breakthrough designation and secured $20,000 Medicare reimbursement per treatment for its cardiac cell therapy after CardiAMP HF trial results showed significant heart function improvements. The company ended Q1 with $951,000 cash, reduced expenses, while the ongoing CardiAMP HF2 trial and Japan regulatory submission proceed.
| Metric | Value |
|---|---|
| Price | $0.97 |
| Market Cap | $10.24M |
| P/E Ratio | -0.76 |
| EPS | $-1.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.20 |
| 52-Week Low | $0.84 |
| Volume | 17.93K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-8.23M |
| Gross Margin | 0.00% |
2 analysts cover BCDA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.50.